AMP kinase acts as a negative regulator of RANKL in the differentiation of osteoclasts.

[1]  Mong-Hong Lee,et al.  The impact of type 2 diabetes and antidiabetic drugs on cancer cell growth , 2010, Journal of cellular and molecular medicine.

[2]  Z. Lee,et al.  Epigallocatechin-3-gallate Inhibits Osteoclastogenesis by Down-Regulating c-Fos Expression and Suppressing the Nuclear Factor-κB Signal , 2010, Molecular Pharmacology.

[3]  B. Kemp,et al.  Germline deletion of AMP‐activated protein kinase β subunits reduces bone mass without altering osteoclast differentiation or function , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[4]  B. Fisslthaler,et al.  Activation and signaling by the AMP-activated protein kinase in endothelial cells. , 2009, Circulation research.

[5]  Gaochao Zhou,et al.  AMPK: an emerging drug target for diabetes and the metabolic syndrome. , 2009, Cell metabolism.

[6]  G. Zhou,et al.  AMPK activators – potential therapeutics for metabolic and other diseases , 2009, Acta physiologica.

[7]  J. B. Kim,et al.  Berberine suppresses proinflammatory responses through AMPK activation in macrophages. , 2009, American journal of physiology. Endocrinology and metabolism.

[8]  A. López-Rivas,et al.  TAK1 activates AMPK‐dependent cytoprotective autophagy in TRAIL‐treated epithelial cells , 2009, The EMBO journal.

[9]  Yan-Hsiung Wang,et al.  (-)-Epigallocatechin gallate inhibition of osteoclastic differentiation via NF-kappaB. , 2009, Biochemical and biophysical research communications.

[10]  J. Suttles,et al.  Adenosine 5′-Monophosphate-Activated Protein Kinase Promotes Macrophage Polarization to an Anti-Inflammatory Functional Phenotype1 , 2008, The Journal of Immunology.

[11]  Y. Uchijima,et al.  AMP-activated Protein Kinase Activation Increases Phosphorylation of Glycogen Synthase Kinase 3β and Thereby Reduces cAMP-responsive Element Transcriptional Activity and Phosphoenolpyruvate Carboxykinase C Gene Expression in the Liver* , 2008, Journal of Biological Chemistry.

[12]  A. Means,et al.  Calcium/calmodulin-dependent kinase IV in immune and inflammatory responses: novel routes for an ancient traveller. , 2008, Trends in immunology.

[13]  P. Sanz,et al.  AMP-activated protein kinase: structure and regulation. , 2008, Current protein & peptide science.

[14]  Ting Han,et al.  Antiosteoporotic chemical constituents from Er-Xian Decoction, a traditional Chinese herbal formula. , 2008, Journal of ethnopharmacology.

[15]  Fan Lan,et al.  SIRT1 Regulates Hepatocyte Lipid Metabolism through Activating AMP-activated Protein Kinase* , 2008, Journal of Biological Chemistry.

[16]  Hui-yu Liu,et al.  Epigallocatechin-3-gallate (EGCG), A Green Tea Polyphenol, Suppresses Hepatic Gluconeogenesis through 5′-AMP-activated Protein Kinase* , 2007, Journal of Biological Chemistry.

[17]  E. Wagner,et al.  NF-κB p50 and p52 Regulate Receptor Activator of NF-κB Ligand (RANKL) and Tumor Necrosis Factor-induced Osteoclast Precursor Differentiation by Activating c-Fos and NFATc1* , 2007, Journal of Biological Chemistry.

[18]  D. Carling,et al.  Investigating the mechanism for AMP activation of the AMP-activated protein kinase cascade. , 2007, The Biochemical journal.

[19]  S. Chien,et al.  Regulation of Endothelial Cell Cycle by Laminar Versus Oscillatory Flow: Distinct Modes of Interactions of AMP-Activated Protein Kinase and Akt Pathways , 2007, Circulation research.

[20]  Akira Yamaguchi,et al.  Regulation of osteoclast differentiation and function by the CaMK-CREB pathway , 2006, Nature Medicine.

[21]  D. Carling,et al.  Thrombin Activates AMP-Activated Protein Kinase in Endothelial Cells via a Pathway Involving Ca2+/Calmodulin-Dependent Protein Kinase Kinase β , 2006, Molecular and Cellular Biology.

[22]  A. Ashworth,et al.  Deficiency of LKB1 in heart prevents ischemia-mediated activation of AMPKalpha2 but not AMPKalpha1. , 2006, American journal of physiology. Endocrinology and metabolism.

[23]  Seungbok Lee,et al.  Antioxidant α-lipoic acid inhibits osteoclast differentiation by reducing nuclear factor-κB DNA binding and prevents in vivo bone resorption induced by receptor activator of nuclear factor-κB ligand and tumor necrosis factor-α , 2006 .

[24]  T. Plesner,et al.  Resveratrol inhibits myeloma cell growth, prevents osteoclast formation, and promotes osteoblast differentiation. , 2005, Cancer research.

[25]  A. Edelman,et al.  Calmodulin-dependent protein kinase kinase-beta is an alternative upstream kinase for AMP-activated protein kinase. , 2005, Cell metabolism.

[26]  Hong-Hee Kim,et al.  α-Lipoic acid suppresses osteoclastogenesis despite increasing the receptor activator of nuclear factor κB ligand/osteoprotegerin ratio in human bone marrow stromal cells , 2005 .

[27]  P. Vestergaard,et al.  Relative fracture risk in patients with diabetes mellitus, and the impact of insulin and oral antidiabetic medication on relative fracture risk , 2005, Diabetologia.

[28]  W. Li,et al.  Effects of trans-resveratrol from Polygonum cuspidatum on bone loss using the ovariectomized rat model. , 2005, Journal of medicinal food.

[29]  D. Hardie.  The AMP-activated protein kinase pathway – new players upstream and downstream , 2004, Journal of Cell Science.

[30]  B. Viollet,et al.  Anti-obesity effects of α-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase , 2004, Nature Medicine.

[31]  N. Fujii,et al.  Symposium 1 : Exercise signalling pathways controlling fuel oxidation during and after exercise Regulation of glucose transport by the AMP-activated protein kinase , 2004 .

[32]  I. Shiojima,et al.  Akt Activity Negatively Regulates Phosphorylation of AMP-activated Protein Kinase in the Heart* , 2003, Journal of Biological Chemistry.

[33]  K. Walsh,et al.  AMP-activated Protein Kinase (AMPK) Signaling in Endothelial Cells Is Essential for Angiogenesis in Response to Hypoxic Stress* , 2003, Journal of Biological Chemistry.

[34]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[35]  Olle Ljunqvist,et al.  Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes. , 2002, Diabetes.

[36]  N. Sakurai,et al.  Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. , 2002, Molecular and cellular biology.

[37]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[38]  D. Hardie,et al.  AMP-activated protein kinase, a metabolic master switch: possible roles in Type 2 diabetes. , 1999, American journal of physiology. Endocrinology and metabolism.

[39]  T. Suzuki,et al.  The effect of kampo formulae on bone resorption in vitro and in vivo. II. Detailed study of berberine. , 1999, Biological & pharmaceutical bulletin.

[40]  D. Brown,et al.  Mitochondria-rich, proton-secreting epithelial cells. , 1996, The Journal of experimental biology.

[41]  G. Radda,et al.  Activation of glycogen phosphorylase and glycogenolysis in rat skeletal muscle by AICAR — an activator of AMP‐activated protein kinase , 1996, FEBS letters.

[42]  Jianping Ye,et al.  Berberine improves glucose metabolism through induction of glycolysis. , 2008, American journal of physiology. Endocrinology and metabolism.